Physician

Matthew Blake Lockwood, MD

According to 2025 Medicare claims, Matthew Lockwood, MD (NPI: 1265875470) practices hematology/oncology in the Fayetteville-Springdale-Rogers, AR market, with the plurality of this provider's patient population coming from Benton, AR. This provider's primary affiliated billing organization is HIGHLANDS ONCOLOGY GROUP PA (NPI: 1346211323; TIN: 710788742) and primary practice location at 72758-8602.

Lockwood's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,547 traditional Medicare patients, billed 331,761 HCPCS/CPT codes, and received $6,622,657 in Medicare payments. The top billing code was 80053 (Blood test, comprehensive group of blood chemicals). Part D data shows 3,148 prescription claims across 482 beneficiaries totaling $5,842,881 in drug costs, led by Xtandi (Enzalutamide). DME data shows 74 claims. Open Payments data shows 48 records totaling $49,131. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,292,021 to $6,622,657. Similarly, Part D prescription costs have risen steadily, from $30,491 to $5,842,881. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	582	80,376	$1,292,021
2020	1,283	296,693	$5,089,363
2021	1,459	298,297	$4,825,520
2022	1,413	323,965	$5,494,982
2023	1,375	358,180	$6,009,899
2024	1,547	331,761	$6,622,657

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	57	826	$30,491
2016	94	703	$25,919
2017	32	82	$58,212
2018	22	32	$41,824
2019	120	257	$221,667
2020	466	1,745	$1,948,727
2021	453	1,952	$2,351,192
2022	424	2,346	$3,962,071
2023	474	2,824	$5,301,811
2024	482	3,148	$5,842,881

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	41	$2,678
2022	N/R	40	$1,566
2023	N/R	97	$8,171
2024	N/R	74	$3,069

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80053	Blood test, comprehensive group of blood chemicals	781	2,460	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	820	2,727	$8
83735	Magnesium level	763	2,384	$7
83615	Lactate dehydrogenase (enzyme) level	757	2,355	$6
84100	Phosphate level	759	2,378	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	93	2,790	$1,173,778
Calquence	Acalabrutinib Maleate	32	960	$483,052
Revlimid	Lenalidomide	32	756	$462,770
Cabometyx	Cabozantinib S-Malate	19	570	$449,704
Nubeqa	Darolutamide	30	900	$377,098

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4385	Ostomy skin barrier, solid 4 x 4 or equivalent, extended wear, without built-in convexity, each	N	N/R	12	$2,126
E0261	Hospital bed, semi-electric (head and foot adjustment), with any type side rails, without mattress	Y	N/R	13	$556
A4394	Ostomy deodorant, with or without lubricant, for use in ostomy pouch, per fluid ounce	N	N/R	11	$200
A4456	Adhesive remover, wipes, any type, each	N	N/R	14	$144
A4367	Ostomy belt, each	N	N/R	11	$24

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	46	$717	Eisai Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$48,414	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Matthew Blake Lockwood, MD?

Tedicare shows public-source Medicare data for Matthew Blake Lockwood, MD (NPI 1265875470), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Matthew Blake Lockwood, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Matthew Blake Lockwood, MD?

Matthew Blake Lockwood, MD is linked to HIGHLANDS ONCOLOGY GROUP PA (billing NPI 1346211323) in the available physician profile data.

Does Matthew Blake Lockwood, MD have Open Payments data?

Matthew Blake Lockwood, MD has 48 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.